Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation.
A series of substituted aryl amide derivatives of 6-naltrexamine, 3 designed to be metabolically stable were synthesized and used to characterize the structural requirements for their potency to binding and functional activity of human mu (mu), delta (delta) and kappa (kappa) opioid and nociceptin (NOP) receptors. Binding assays showed that 4-10 had subnanomolar K(i) values for mu and kappa opioid receptors. Functional assays for stimulation of [(35)S]GTPgammaS binding showed that several compounds acted as partial or inverse agonists and antagonists of the mu and delta, kappa opioid or NOP receptors. The compounds showed considerable stability in the presence of rat, mouse or human liver preparations and NADPH. The inhibitory activity on the functional activity of human cytochrome P450s was examined to determine any potential inhibition by 4-9. Only modest inhibition of CYP3A4, CYP2C9 and CYP2C19 was observed for a few of the analogs. As a representative example, radiolabeled 6 was examined in vivo and showed reasonable brain penetration. The inhibition of ethanol self-administration in rats trained to self-administer a 10% (w/v) ethanol solution, utilizing operant techniques showed 5-8 to have very potent efficacy (ED(50) values 19-50 microg/kg).
Ghirmai
Senait
S
Human BioMolecular Research Institute, 5310 Eastgate Mall, San Diego, CA 92121, USA.
Azar
Marc R
MR
Cashman
John R
JR
D000427:Alcohol Deterrents / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D000437:Alcoholism / Q000188:drug therapy*; D000818:Animals; D006801:Humans; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D009271:Naltrexone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D011485:Protein Binding; D051381:Rats; D017208:Rats, Wistar; D011957:Receptors, Opioid / Q000378:metabolism*; D017465:Receptors, Opioid, delta / Q000378:metabolism; D017473:Receptors, Opioid, kappa / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000378:metabolism; D013329:Structure-Activity Relationship; D000094942:Nociceptin Receptor
D000427:Alcohol Deterrents; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D009271:Naltrexone; C035438:beta-naltrexamine; D000094942:Nociceptin Receptor
Addiction. 2004 Jul;99(7):811-28
15200577
Alcohol Clin Exp Res. 1998 Dec;22(9):2174-85
9884166
Life Sci. 1983 Jan 17;32(3):197-204
6296588
J Med Chem. 2000 Jul 13;43(14):2759-69
10893314
Neuropsychopharmacology. 2006 Jul;31(7):1489-99
16237389
J Med Chem. 2006 Nov 30;49(24):6987-7001
17125252
Curr Top Med Chem. 2005;5(6):585-94
16022681
J Biol Chem. 1981 Oct 10;256(19):10017-23
6268622
Neuropsychopharmacology. 2008 Feb;33(3):643-52
17473837
Psychopharmacology (Berl). 1999 Aug;145(4):360-9
10460312
Am J Psychiatry. 1999 Nov;156(11):1758-64
10553740
Alcohol. 1993 Mar-Apr;10(2):127-32
8095143
J Med Chem. 2004 Nov 4;47(23):5809-15
15509180
Eur Neuropsychopharmacol. 2006 Jul;16(5):311-23
16361086
Alcohol Clin Exp Res. 1997 Aug;21(5):784-91
9267526
J Med Chem. 2008 Mar 27;51(6):1913-24
18298057
Addict Biol. 2006 Sep;11(3-4):397-403
16961767
Arch Gen Psychiatry. 1997 Dec;54(12):1130-5
9400350
Drug Metab Dispos. 1997 Aug;25(8):1001-7
9280409
Arch Gen Psychiatry. 1999 Aug;56(8):719-24
10435606
Am J Clin Nutr. 1985 Nov;42(5 Suppl):1099-132
2865892
Brain Res. 1993 Sep 3;621(1):137-40
7693299
J Pharmacol Exp Ther. 2000 Jun;293(3):1002-8
10869404
Psychopharmacology (Berl). 1997 Jan;129(2):99-111
9040115
J Med Chem. 2009 Mar 12;52(5):1416-27
19199782
Neurosci Biobehav Rev. 2002 Oct;26(6):713-28
12479844
Arch Gen Psychiatry. 1996 Mar;53(3):250-7
8611062
Biochem Pharmacol. 1973 Dec 1;22(23):3099-108
4202581
J Clin Psychiatry. 1995;56 Suppl 7:5-14
7673105
Biochem Pharmacol. 2004 Feb 15;67(4):751-6
14757175
Alcohol. 2001 Feb;23(2):109-16
11331108
Alcohol Clin Exp Res. 1999 Sep;23(9):1468-76
10512312
Drug Metab Rev. 2006;38(4):641-9
17145693
Neuropsychopharmacology. 2003 Aug;28(8):1463-71
12700689
Drug Metab Rev. 1984;15(5-6):1163-82
6396055
Mol Pharmacol. 1995 Apr;47(4):848-54
7723747
J Biol Chem. 1989 Feb 5;264(4):1988-97
2914890